SCHEMBL5865009

SCHEMBL5865009

CCc1cc([N+](=O)[O-])cc(Br)[n+]1[O-]

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.44
POLB P06746 1/20 0.44
ESPL1 Q14674 3/20 0.40
TSHR P16473 1/20 0.38
CYP19A1 P11511 1/20 0.36
ALDH1A1 P00352 5/20 0.36
CYP3A4 P08684 2/20 0.36
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
LMNA P02545 1/20 0.35
MAPT P10636 2/20 0.33
TDP1 Q9NUW8 1/20 0.33
GALR3 O60755 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
NPC1 O15118 1/20 0.32
CHEK1 O14757 1/20 0.32
DAPK3 O43293 1/20 0.32
GRK5 P34947 1/20 0.32
LIMK1 P53667 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26688824 0.87 HTT (0.52) HTTPOLBESPL1TSHRCYP19A1
SCHEMBL19975766 0.81 HTT (0.43) HTTPOLBESPL1TSHRCYP19A1
SCHEMBL782341 0.81 CYP19A1 (0.48) HTTPOLBESPL1TSHRCYP19A1
SCHEMBL3560709 0.81 HTT (0.46) HTTPOLBESPL1TSHRCYP19A1
SCHEMBL11842588 0.79 HTT (0.44) HTTPOLBESPL1TSHRCYP19A1
SCHEMBL11609774 0.79 HTT (0.53) HTTPOLBESPL1TSHRCYP19A1
SCHEMBL942208 0.77 TSHR (0.47) HTTPOLBESPL1TSHRCYP19A1
SCHEMBL27546397 0.72 ESPL1 (0.40) HTTPOLBESPL1TSHRCYP19A1
SCHEMBL695579 0.70 POLB (0.42) HTTPOLBESPL1TSHRALDH1A1
SCHEMBL1684427 0.68 HTT (0.52) HTTPOLBESPL1TSHRCYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100516061-C Pyridine derivatives as NMDA receptor ligands HOFFMANN LA ROCHE (CH) 2009-07-22 CN disclosed
CN-1837195-A Pyridine derivatives as nmda-receptor subtype blockers HOFFMANN LA ROCHE (CH) 2006-09-27 CN disclosed
US-7034044-B2 Conjugated aromatic compounds with a pyridine substituent HOFFMANN-LA ROCHE INC. (US) 2006-04-25 US disclosed
US-20060058354-A1 Conjugated aromatic compounds with a pyridine substituent ALANINE ALEXANDER 2006-03-16 US disclosed
US-6951875-B2 Conjugated aromatic compounds with a pyridine substituent HOFFMANN-LA ROCHE INC. (US) 2005-10-04 US disclosed
EP-1448547-B1 PYRIDINE DERIVATIVES AS NMDA RECEPTOR LIGANDS HOFFMANN LA ROCHE (CH) 2005-04-20 EP disclosed
CN-1585762-A Pyridine derivatives as NMDA receptor ligands HOFFMANN LA ROCHE (CH) 2005-02-23 CN disclosed
CN-1578662-A Pyridine derivatives as nmda-receptor subtype blockers HOFFMANN LA ROCHE (CH) 2005-02-09 CN disclosed
US-6831087-B2 2-(Pyrid-2- or 4-yl)-1,2,3,4-tetrahydroisoquinoline and derivatives; a good affinity to the NMDA receptor (N-methyl-D-asparate); acute/cronic neurodegenerative diseases; bacterial/viral infections; antidepressants; analgesics HOFFMANN-LA ROCHE INC. 2004-12-14 US disclosed
EP-1448547-A1 PYRIDINE DERIVATIVES AS NMDA RECEPTOR LIGANDS F. HOFFMANN-LA ROCHE AG (CH) 2004-08-25 EP disclosed
EP-1443926-A1 PYRIDINE DERIVATIVES AS NMDA-RECEPTOR SUBTYPE BLOCKERS F. HOFFMANN-LA ROCHE AG (CH) 2004-08-11 EP disclosed
US-20040068118-A1 Conjugated aromatic compounds with a pyridine substituent ALANINE ALEXANDER (FR) 2004-04-08 US disclosed
US-20030144525-A1 Conjugated aromatic compounds with a pyridine substituent HOFFMANN-LA ROCHE INC. 2003-07-31 US disclosed
US-20030119870-A1 Pyridine substituted isoquinoline derivatives F. HOFFMANN-LA ROCHE AG (CH) 2003-06-26 US disclosed
WO-2003040128-A1 PYRIDINE DERIVATIVES AS NMDA RECEPTOR LIGANDS F. HOFFMANN-LA ROCHE AG (CH) 2003-05-15 WO disclosed
WO-2003037333-A1 PYRIDINE DERIVATIVES AS NMDA-RECEPTOR SUBTYPE BLOCKERS F. HOFFMANN-LA ROCHE AG (CH) 2003-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040068118-A1 Conjugated aromatic compounds with a pyridine substituent GRIN2B, GRIN1, GRIN2C HTT 1397/4885POLB 3116/4885ESPL1 4642/4885
US-20030144525-A1 Conjugated aromatic compounds with a pyridine substituent GRIN2B, GRIN1, GRIN2C HTT 1397/4885POLB 3116/4885ESPL1 4642/4885
US-20060058354-A1 Conjugated aromatic compounds with a pyridine substituent GRIN2B, GRIN3A, GRIN2C HTT 1359/4885POLB 2949/4885ESPL1 4406/4885
US-20030119870-A1 Pyridine substituted isoquinoline derivatives GRIN1, GRIN2C, GRIN2A HTT 1686/4885POLB 3481/4885ESPL1 4628/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.